CAGR of 15.6% Projected for Pancreatic Cancer Drugs Market From 2025 to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Does the Forecast Indicate for the Pancreatic Cancer Drugs Market From 2025 to 2029?
The market size of next-generation drug conjugates has experienced a swift expansion in the past few years. The market value is expected to elevate from $2.15 billion in 2024 to $2.47 billion in 2025, with a compound annual growth rate (CAGR) of 14.8%. This growth during the historical period can be linked to the improved comprehension of tumor biology, the accomplishment of early drug conjugates, a rise in oncology, increased investments and funding, as well as enhanced patient advocacy and consciousness.
The market size of next-generation drug conjugates is slated for substantial expansion in the coming years. Expected to soar to “$4.41 billion in 2029 with a compound annual growth rate (CAGR) of 15.6%. Influencing factors for the predicted progress in the forecast period includes the rise in combination therapies, expansion of clinical research, emphasis on rare diseases, strategic collaborations, and the advent of bioinformatics tools. Significant trends anticipated within the forecast period encompass progresses in monoclonal antibody technology, combination therapies incorporating JAK inhibitors, incorporation of artificial intelligence in drug developments, the advent of biosimilars, and advancements in subcutaneous formulations.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19124&type=smp
What Elements Are Contributing To Growth In The Pancreatic Cancer Drugs Market?
The escalation in the frequency of pancreatic cancer is projected to stimulate the expansion of the pancreatic cancer drugs market. As the number of pancreatic cancer diagnoses soars, so does the need for medication, fuelling the expansion of the pancreatic cancer drugs market. The rise in cancer cases is primarily attributed to the growing elderly population and an uptick in the number of individuals afflicted with obesity. For example, the American Cancer Society predicts that approximately 64,050 individuals (33,130 men and 30,920 women) will be diagnosed with pancreatic cancer in 2023, with roughly 50,550 people (26,620 men and 23,930 women) expected to succumb to the disease.
The next generation drug conjugates market covered in this report is segmented –
1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate
2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles
3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule
4) By Therapy: Monotherapy, Combination Therapy
5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications
Subsegments:
1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides
2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates
3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates
4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates
Which Trends Are Redefining The Future Landscape Of The Pancreatic Cancer Drugs Industry?
Leading businesses in the next-generation drug conjugates market are utilizing strategic partnerships as a method to boost their research and development abilities, propel product innovation, and increase their market footprint. Strategic partnerships are defined as a symbiotic relationship where companies exploit one another’s assets and strengths in order to accomplish shared objectives and triumphs. For example, in November 2023, Prelude Therapeutics Incorporated, a US precision oncology company in the clinical stage, collaborated with AbCellera Biologics Inc., a biotech company based in Canada. Their goal is to produce state-of-the-art precision antibody-drug conjugates (ADCs) for cancer treatment. The focus of their collaboration will be the discovery, development, and marketing of ground-breaking antibody-drug conjugates (ADCs), beginning with a program targeting a SMARCA degrader attached to a novel antibody. The intention of this approach is to extend the therapeutic uses of Prelude’s selective SMARCA2 degraders to a larger group of patients, notably those whose cancers are not associated with SMARCA4 mutations.
Who Are The Key Contributors To Growth In The Pancreatic Cancer Drugs Market?
Major companies operating in the next generation drug conjugates marker are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH
Which Region Is Projected To Lead The Pancreatic Cancer Drugs Market By 2025?
North America was the largest region in the next generation drug conjugates market in 2024. The regions covered in the next generation drug conjugates marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19124&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
